Troiani T - Search Results

1

Differential Diagnosis: Retroperitoneal Fibrosis and Oncological Diseases.

Sica A, Casale B, Spada A, Teresa Di Dato M, Sagnelli C, Calogero A, Buonavolontà P, Salzano A, Martinelli E, Saracco E, Troiani T, Anna Dodaro C, Tammaro D, Luisa De Rimini M, Ciardiello F, Papa A. Sica A, et al. Among authors: troiani t. Open Med (Wars). 2019 Dec 26;15:22-26. doi: 10.1515/med-2020-0005. eCollection 2018. Open Med (Wars). 2019. PMID: 31922016 Free PMC article.

2

Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.

Bianco R, Troiani T, Tortora G, Ciardiello F. Bianco R, et al. Among authors: troiani t. Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S159-71. doi: 10.1677/erc.1.00999. Endocr Relat Cancer. 2005. PMID: 16113092 Review.

3

Erlotinib in cancer treatment.

Bareschino MA, Schettino C, Troiani T, Martinelli E, Morgillo F, Ciardiello F. Bareschino MA, et al. Among authors: troiani t. Ann Oncol. 2007 Jun;18 Suppl 6:vi35-41. doi: 10.1093/annonc/mdm222. Ann Oncol. 2007. PMID: 17591829 Free article. Review.

4

The use of xenograft models for the selection of cancer treatments with the EGFR as an example.

Troiani T, Schettino C, Martinelli E, Morgillo F, Tortora G, Ciardiello F. Troiani T, et al. Crit Rev Oncol Hematol. 2008 Mar;65(3):200-11. doi: 10.1016/j.critrevonc.2007.10.003. Crit Rev Oncol Hematol. 2008. PMID: 18389522 Review.

5

Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells.

Morgillo F, Martinelli E, Troiani T, Laus G, Pepe S, Gridelli C, Ciardiello F. Morgillo F, et al. Among authors: troiani t. Mol Cancer Ther. 2008 Jun;7(6):1698-707. doi: 10.1158/1535-7163.MCT-07-0547. Mol Cancer Ther. 2008. PMID: 18566241

6

Resistance mechanisms of tumour cells to EGFR inhibitors.

Morgillo F, Cantile F, Fasano M, Troiani T, Martinelli E, Ciardiello F. Morgillo F, et al. Among authors: troiani t. Clin Transl Oncol. 2009 May;11(5):270-5. doi: 10.1007/s12094-009-0354-6. Clin Transl Oncol. 2009. PMID: 19451059 Review.

7

Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.

Morgillo F, D'Aiuto E, Troiani T, Martinelli E, Cascone T, De Palma R, Orditura M, De Vita F, Ciardiello F. Morgillo F, et al. Among authors: troiani t. Lung Cancer. 2011 Mar;71(3):283-90. doi: 10.1016/j.lungcan.2010.06.005. Lung Cancer. 2011. PMID: 20619923 Retracted.

8

Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care.

Martinelli E, Morgillo F, Troiani T, Tortora G, Ciardiello F. Martinelli E, et al. Among authors: troiani t. Core Evid. 2007 Nov 30;2(2):81-8. Core Evid. 2007. PMID: 21221177 Free PMC article.

9

Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors.

Morgillo F, Martinelli E, Troiani T, Orditura M, De Vita F, Ciardiello F. Morgillo F, et al. Among authors: troiani t. PLoS One. 2011;6(12):e28841. doi: 10.1371/journal.pone.0028841. Epub 2011 Dec 9. PLoS One. 2011. PMID: 22174910 Free PMC article. Retracted.

10

Targeting EGFR in pancreatic cancer treatment.

Troiani T, Martinelli E, Capasso A, Morgillo F, Orditura M, De Vita F, Ciardiello F. Troiani T, et al. Curr Drug Targets. 2012 Jun;13(6):802-10. doi: 10.2174/138945012800564158. Curr Drug Targets. 2012. PMID: 22458527 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

196 results

Search Page